Durham VA Medical Center, Durham, NC
Durham, North Carolina, 27705-3875, United States
NCT Number: NCT01142908
Cardiovascular disease (CVD) is the leading cause of death in the United States; more than 80% of veterans have > 2 risk factors for CVD. Our study is one of the first to examine the implementation of a tailored behavioral/educational self-management intervention in primary care clinics designed to improve CVD risk. The proposed study could result in a leap forward in CVD risk management among veterans for several reasons: 1) ) This is a novel extension of our previous interventions that have demonstrated improved BP, now designed to address multiple chronic conditions contributing to CVD risk, particularly hyperlipidemia and diabetes. The study focuses on both multiple CVD-related risk factor management and medication management 2) The intervention is multi-behavioral; it addresses patients' various health behavior (e.g., smoking, diet, and medication adherence). 3) Components of the intervention will include specific recommendations and transportability of intervention application software and tracking packages that will allow clinic managers to implement the intervention if it is effective.
Looking for future studies?
Notify MeAll sexes
Interventional
Not applicable
Durham, North Carolina, 27705-3875, United States
Anticipated Impacts on Veteran's Healthcare: Cardiovascular disease (CVD) is the leading cause of death in the U.S.; more than 80% of veterans have > 2 risk factors for CVD. An intervention that addresses multiple CVD risk factors among high-risk veterans has the greatest potential to improve morbidity and mortality.
Project Background/Rationale: The proposed study will take place in two VA primary care clinics (1-Community-Based Outpatient Clinics and 1-primary care clinic affiliated with a hospital). We will improve CVD risk among veterans by addressing the modifiable risk factors of systolic blood pressure (SBP), smoking, and low-density lipoprotein cholesterol (LDL-C). The intervention will be tailored to the needs of vulnerable high risk patients (e.g. African Americans, low literate) and integrated into clinics, thereby enhancing the potential for benefit and generalizability to other settings.
The proposed study could significantly improve CVD risk management among veterans for several reasons: 1) This intervention is a novel extension of our previous efficacious interventions, but provides a novel extension to address multiple chronic conditions contributing to CVD risk. 2) The intervention focuses on both multiple CVD-related behaviors and medication management. 3) The intervention was developed to ensure implementation across a large and representative sample of veterans; and; 4) The intervention, if found efficacious and financially self-sustaining, could be widely implemented within the VA healthcare system.
Project Objectives: The proposed study will examine two research questions:
Secondary Hypotheses: (H2) Veterans who receive the intervention will have improved medication adherence, physical activity, improved diet, lower body mass index as compared to the control group over 12 months of follow-up. (H3) Veterans who receive the intervention will have greater improvements in LDL over the 12 months of follow-up as compared to the control group. (H4) Veterans with diabetes who receive the intervention will have greater improved HbA1c as compared to the control group over 12 months of follow-up.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
clinical pharmacist-administered intervention which focuses on behavioral and medication management for 12 months.
Time frame: Baseline
Components of the Framingham include gender, age fixed at baseline, systolic blood pressure (presence/absence of blood pressure medications at each time point [combination of administrative med data pull and self-report at assessment]), total cholesterol, HDL cholesterol, smoking status (assessed via self-report at each study survey), and diabetes (diabetes is a combination of self-report and VA Computerized Patient Record System (CPRS) data review). "New cases" of diabetes are allowed to be updated at 6 and 12 months f/u.
Time frame: 6 months
Components of the Framingham include gender, age fixed at baseline, systolic blood pressure (presence/absence of blood pressure medications at each time point [combination of administrative med data pull and self-report at assessment]), total cholesterol, HDL cholesterol, smoking status (assessed via self-report at each study survey), and diabetes (diabetes is a combination of self-report and CPRS data review). "New cases" of diabetes are allowed to be updated at 6 and 12 months f/u.
Time frame: 12 months
Components of the Framingham include gender, age fixed at baseline, systolic blood pressure (presence/absence of blood pressure medications at each time point [combination of administrative med data pull and self-report at assessment]), total cholesterol, HDL cholesterol, smoking status (assessed via self-report at each study survey), and diabetes (diabetes is a combination of self-report and CPRS data review). "New cases" of diabetes are allowed to be updated at 6 and 12 months f/u.
Time frame: Baseline
Mean BP is calculated as the average of 3 bp measurements. Collected during BP outcome measurement conducted at interviews
Time frame: 6 months
Mean BP is calculated as the average of 3 bp measurements. Collected during BP outcome measurement conducted at interviews
Time frame: 12 months
Mean BP is calculated as the average of 3 bp measurements. Collected during BP outcome measurement conducted at interviews
Time frame: Baseline
Mean BP is calculated as the average of 3 bp measurements. Collected during BP outcome measurement conducted at interviews
Time frame: 6 months
Mean BP is calculated as the average of 3 bp measurements. Collected during BP outcome measurement conducted at interviews
Time frame: 12 months
Mean BP is calculated as the average of 3 bp measurements. Collected during BP outcome measurement conducted at interviews
Time frame: Baseline
First 4 items of the 5 item Morisky Self-reported measure of medication adherence was used to determine medication non-adherence.
Time frame: 6 months
First 4 items of the 5 item Morisky Self-reported measure of medication adherence was used to determine medication non-adherence.
Time frame: 12 months
First 4 items of the 5 item Morisky Self-reported measure of medication adherence was used to determine medication non-adherence.
Time frame: Baseline
Collected during interview visit by lab personnel
Time frame: 6 months
Collected during interview visit by lab personnel
Time frame: 12 months
Collected during interview visit by lab personnel
Time frame: Baseline
Calculated from vitals (height & weight) obtained during interview
Time frame: 6 months
Calculated from vitals (height & weight) obtained during interview
Time frame: 12 months
Calculated from vitals (height & weight) obtained during interview
Time frame: Baseline
Lab values collected at interview visit by lab personnel
Time frame: 6 months
Lab values collected at interview visit by lab personnel
Time frame: 12 months
Lab values collected at interview visit by lab personnel
VA Office of Research and Development
Fed
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02742597
Alzheimer Disease, Alzheimer's Disease
London, Ontario, Canada
View Trial DetailsNCT02789800
Alzheimer Disease, Alzheimer's Disease
Chicoutimi, Quebec, Canada
View Trial DetailsNCT02215408
Cardiovascular Disease, Cardiovascular Diseases
Gainesville, Florida, United States
View Trial DetailsNCT00147251
Brain Diseases, Cardiovascular Disease
Chinle, Arizona, United States
View Trial Details